Extended Half-Life Factor VIII and Factor IX Preparations

Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie
Lukas Graf

Abstract

In the last couple of years, several extended half-life factor VIII and factor IX preparations were intensively studied and gained approval. In order to extend half-lives, techniques like fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification are implemented. With these techniques, it is possible to extend half-lives of factor IX products 4- to 6- fold, while half-life extension of factor VIII products is limited to 1.5- to 2-fold due to their interaction with von Willebrand factor. Nevertheless, both extended half-life factor VIII and IX products have improved and facilitated prophylactic factor replacement therapy in hemophilia A and B, respectively. Extended half-life factor concentrates pose challenges to coagulation laboratories because accurate therapy monitoring is not possible with all factor activity assays currently used.

Citations

Apr 24, 2019·The Journal of Pharmacology and Experimental Therapeutics·A R Satvik IyengarAbhay H Pande
Dec 7, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Amanda B PayneConnie H Miller
Mar 3, 2020·Journal of Thrombosis and Haemostasis : JTH·Flora PeyvandiMichael Spannagl
Aug 29, 2020·Journal of Managed Care & Specialty Pharmacy·Mindy L SimpsonSongkai Yan
Sep 17, 2020·Clinical Pharmacokinetics·Tim PreijersRon A A Mathôt
Sep 17, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Jun SuRonald Preblick
Mar 27, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Elena SantagostinoMacGregor Steele
Jun 7, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Katsuyuki FukutakeToshiyuki Karumori
Sep 5, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Shannon L Meeks, Sébastien Lacroix-Desmazes
Feb 3, 2021·Journal of Thrombosis and Haemostasis : JTH·Haarin ChunAndrey G Sarafanov
Feb 25, 2021·European Journal of Clinical Pharmacology·Tim PreijersRon Mathôt
Dec 18, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·John S S ButterfieldRadoslaw Kaczmarek
May 21, 2021·Journal of Thrombosis and Haemostasis : JTH·Olav VerslootUNKNOWN Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG)
Jul 23, 2021·BMJ Case Reports·Shireen I Alzadjali, Yasser Wali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.